|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/44 | |
| A61K 31/198 | |||
| A61K 9/00 |
| (11) | Number of the document | 2635256 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11838922.0 |
| Date of filing the European patent application | 2011-11-04 | |
| (97) | Date of publication of the European application | 2013-09-11 |
| (45) | Date of publication and mention of the grant of the patent | 2020-10-21 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2011/059466 |
| Date | 2011-11-04 |
| (87) | Number | WO 2012/061787 |
| Date | 2012-05-10 |
| (30) | Number | Date | Country code |
| PCT/US2010/0556 | 2010-11-05 | WO |
| (72) |
BANDAK, Stephen, I., US
BLACK, Kevin, J., US
CAMPBELL, Meghan, C., US
|
| (73) |
Biotie Therapies, Inc.,
601 Gateway Boulevard, Suite 1200, South San Francisco, CA 94080,
US
|
| (54) | A2A ANTAGONISTS AS COGNITION AND MOTOR FUNCTION ENHANCERS |
| A2A ANTAGONISTS AS COGNITION AND MOTOR FUNCTION ENHANCERS |